Eli Lilly reported Phase 3b one-year data showing that combining Taltz (ixekizumab) with Zepbound (tirzepatide) improved and sustained outcomes in adults with psoriatic disease and obesity. While specific efficacy metrics weren’t provided in the excerpt, the update is a positive clinical signal that could support commercial momentum for both franchises.
Eli Lilly reported Phase 3b one-year data showing that combining Taltz (ixekizumab) with Zepbound (tirzepatide) improved and sustained outcomes in adults with psoriatic disease and obesity. While specific efficacy metrics weren’t provided in the excerpt, the update is a positive clinical signal that could support commercial momentum for both franchises.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
